Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences, Inc.

http://www.gilead.com

Latest From Gilead Sciences, Inc.

Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19

Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.

Coronavirus COVID-19 Vaccines

FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation

Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.

Coronavirus COVID-19 Clinical Trials

J.P. Morgan Day 4: Setting Goals For The Year Ahead

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC. 

Business Strategies Companies

J.P. Morgan Day 4: Setting Goals For The Year Ahead

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC. 

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Arresto Biosciences, Inc.
    • Asegua Therapeutics, LLC
    • Calistoga Pharmaceuticals, Inc.
    • CGI Pharmaceuticals, Inc.
    • CV Therapeutics, Inc.
    • Cytopia Limited
    • EpiTherapeutics
    • Eximias Pharmaceutical Corporation
    • Immunomedics, Inc.
    • Myogen
    • Nimbus Apollo, Inc.
    • Nexstar Pharmaceuticals
    • Oligogen, Inc.
    • Pharmasset, Inc.
    • Triangle Pharmaceuticals
    • YM BioSciences Inc. (YMI)
    • Kite Pharma, Inc.
    • Kite Pharma EU
    • T-Cell Factory B.V. (TCF)
    • Cell Design Labs, Inc.
    • Asegua Therapeutics
UsernamePublicRestriction

Register